Eletriptan for acute migraine

Smith, L; Oldman, AD; McQuay, HJ; Moore, R Andrew

doi:10.1002/14651858.cd003224

Cited by 7 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An earlier Cochrane review of eletriptan for acute migraine was withdrawn from publication (Smith 2007). It is important to reassess and re-analyse the data from that review together with the newer evidence now available.…”

Section: Back Groundmentioning

confidence: 99%

See 1 more Smart Citation

Eletriptan for acute migraine headaches in adults

Derry¹,

Moore²,

McQuay³

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Section: Back Groundmentioning

confidence: 99%

“…: CD003224. DOI: 10.1002/14651858.CD003224.pub2 (Smith 2007; originally published in 2001, Issue 3; withdrawn in 2007, Issue 1). That review was withdrawn at the request of the Cochrane Funding Arbitration Panel after a change in the The Cochrane Collaboration’s commercial sponsorship policy.…”

mentioning

confidence: 99%

Eletriptan for acute migraine headaches in adults

Derry¹,

Moore²,

McQuay³

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Within recent years several systematic reviews with meta-analyses of acute migraine treatment have been published (37)(38)(39)(40)(41)(42)(43)(44)(45)(46). In addition, three systematic reviews of preventive migraine treatment have been published (47)(48)(49).…”

Section: Systematic Reviews In Migrainementioning

confidence: 99%

“…In the systematic reviews of acute migraine treatment (37–43, 45, 46) migraine was diagnosed according to the criteria of the International Headache Society (IHS) (50) and the same methodology was used (14). Patients treated moderate or severe headache and headache relief was defined as a decrease to none or mild (13).…”

Section: Systematic Reviews In Migrainementioning

confidence: 99%

A Review of Evidence-Based Medicine and Meta-Analytic Reviews in Migraine

Tfelt‐Hansen

2006

Cephalalgia

View full text Add to dashboard Cite

The following systematic reviews and meta-analyses are presented and the results discussed: the evidence-based American guidelines, five systematic reviews on naratriptan, rizatriptan, eletriptan, sumatriptan and propranolol; a meta-analysis of sumatriptan, a meta-analysis of acute migraine therapy, a meta-analysis of triptans available in Canada and a large meta-analysis of oral triptans. The systematic reviews of several randomized trials of one drug overcome random effects in estimating treatment effect of the reviewed drug. The results from the large meta-analysis of several drugs are compared with head-to-head comparative trials. Results are generally the same in the meta-analysis and in the comparative trials, with some exceptions. Head-to-head comparisons should remain the 'gold standard' and meta-analyses are a useful supplement in cases when comparative trials are relatively small and when no comparative trials exist.

show abstract

“…Both found eletriptan, rizatriptan and almotriptan to be the most effective of the oral triptans available. A Cochrane analysis gives overall information on the evidence of efficacy available in the literature [24].…”

Section: Clinical Efficacymentioning

confidence: 99%

Eletriptan: a review and new perspectives

Sandrini

Perrotta

Nappi

2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Eletriptan is a second-generation 5-hydroxytryptamine(1B/1D) receptor agonist, or triptan, indicated for the acute treatment of migraine. Eletriptan has a favorable pharmacokinetic and pharmacodynamic profile expressed by bioavailability, half-life and high selectivity for cranial arteries. It has been shown to be effective and well tolerated in a wide preapproval development program, which included over 11,000 patients and treated more than 74,000 migraine attacks. In clinical trials, eletriptan has been demonstrated to be one of the most effective oral therapies for the acute treatment of migraine and has shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

show abstract

Eletriptan for acute migraine

Cited by 7 publications

References 14 publications

Eletriptan for acute migraine headaches in adults

Eletriptan for acute migraine headaches in adults

A Review of Evidence-Based Medicine and Meta-Analytic Reviews in Migraine

Eletriptan: a review and new perspectives

Contact Info

Product

Resources

About